Pre-market hot trades in US stocks: Texas Instruments up 5.24% in pre-market; ON Semiconductor up 5.22% in pre-market

Pre-market Hot Trades in US Stocks

Texas Instruments is up 5.24% in pre-market trading. Based on recent key news:

1. On July 14, Keybanc raised the target price for Texas Instruments from $325 to $390, driving the stock price up. Analyst John Vinh maintained a buy rating, indicating increased market confidence in its future performance.

2. On July 14, the inventory adjustment in the industrial terminal market was delayed, affecting the cyclical recovery of Texas Instruments. Despite facing free cash flow pressures and weakened demand in the automotive market, AI-driven demand for power infrastructure provides growth opportunities.

3. On July 14, sales of AI-related analog chips are expected to grow by 50%-100%, and Texas Instruments is likely to benefit from this. BofA predicts an improvement in industrial demand, with customers beginning to replenish analog hardware inventory, enhancing market expectations. AI demand is driving growth in the analog chip market.

ON Semiconductor is up 5.22% in pre-market trading. Based on recent key news:

1. On July 14, ON Semiconductor was rated a buy by 24/7 Wall St. due to the accelerated development of AI data centers, with a target price of $123.74. Analysts believe that the recovery of its profit margins is a key factor driving the stock price up.

2. On July 14, BofA predicts that sales of AI-related analog chips will grow by 50%-100%, benefiting companies like ON Semiconductor from improved industrial demand and customer inventory replenishment, driving stock prices up.

3. On July 12, demand for electrification is driving the demand for SiC and GaN power silicon, and ON Semiconductor, as a scaled compound grower, benefits from the electrification wave, with significant capital inflow. The demand for AI chips is strong, and the industry outlook is optimistic.

Top Gainers in Pre-market US Stocks

NextCure is up 314.22% in pre-market trading. Based on recent news:

1. On July 14, NextCure announced a merger with Avere Therapeutics and will operate under the name Avere Therapeutics. This news significantly boosted NextCure's stock price. After the merger, Avere shareholders will hold approximately 98.8% of the merged company, while NextCure shareholders will hold only about 1.2%.

2. On July 14, NextCure announced it has secured $320 million in private financing to develop AVR-001, an experimental weekly drug for inflammatory diseases. This financing news further boosted market confidence, driving the stock price up.

3. On July 14, NextCure's stock price saw a surge in trading volume after the merger announcement, with over 44 million shares changing hands, while the company's average daily trading volume over the past three months was about 37,000 shares. The surge in trading volume indicates a strong market reaction to the news. The biotechnology sector has been active recently, with significant capital inflow U-BX Tech pre-market rose 65.08%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Shuttle Pharmaceuticals pre-market rose 51.35%. Based on recent news,

1. On July 13, HRT Financial LP increased its direct holdings in Shuttle Pharmaceuticals to 61,271 shares. HRT Financial purchased 8,997 shares in the open market at prices ranging from $3.11 to $3.38 per share. Following this news, market demand for the stock significantly increased, driving the stock price up sharply.

2. On July 13, HRT Financial reported in Form 3 that its holding in Shuttle Pharmaceuticals reached 10%. As of July 9, HRT Financial directly held 60,540 shares of common stock. This increase in holdings was interpreted by the market as confidence in the company's prospects, further driving up the stock price. The market holds an optimistic view of the company's prospects, with significant capital inflow